Research Article ISSN 2639-9512

Stem Cell & Regenerative Medicine

Stem Cell Treatments for Type 2 Diabetes

Jonathan RT Lakey[1-3, 8*], Carolina Bluguermann[4], Ian Jenkins[2], Krista Casazza[1,8], Waldemar Learnhardt[2], Bradley Robinson[3], Adrian Mutto[2,3], Diana Andrade[5], Araceli Medina-Nolasco[5], Andrea Gutiérrez-Contreras[5,6], Paul de Vos[7], Robert Bramblett[8] and Pedro Gutierrez-Castrellon[3,5]

[1]*Department of Surgery and Biomedical Engineering, University of California Irvine, Irvine, CA 92868, USA.*

[2]*GATC Health Inc, Suite 660, 2030 Main Street, Irvine CA 92614, USA.*

[3]*Cellarion Health Inc, Sheridan, WY, 82801, USA.*

[4]*Instituto de Investigaciones Biotecnológicas IIBIO Dr Rodolfo Ugalde Universidad Nacional de San Martín (UNSAM). Buenos Ares, Argentina.*

[5]*Elemental Traslational Research SAPI, Mexico City, Mexico.*

[6]*Instituto Tecnológico de Monterrey. Campus CDMX, Mexico.*

[7]*Faculty of Science and Engineering, Maastricht University Campus Venlo, Venlo, The Netherlands*

[8]*Purity Health LLC, Columbia TN, USA.*

[*]Correspondence:

Dr. Jonathan RT Lakey, PhD, MSM, Professor Emeritus, Surgery and Biomedical Engineering, University of California Irvine, California, USA.

Received: 02 Jan 2026; **Accepted:** 05 Feb 2026; **Published:** 19 Feb 2026

Citation: Jonathan RT Lakey, Carolina Bluguermann, Ian Jenkins, et al. Stem Cell Treatments for Type 2 Diabetes. Stem Cells Regen Med. 2026; 10(1): 1-9.

ABSTRACT

Background: *Type 1 and type 2 diabetes mellitus (T1D, T2D) represent global health challenges, projected to affect nearly 800 million individuals by 2050. Standard pharmacologic and insulin-based therapies manage hyperglycemia but fail to restore durable endogenous insulin secretion or halt disease progression. Stem cell–based therapies have emerged as a transformative modality, offering the potential for β-cell replacement, immune modulation, and systemic metabolic benefit.*

Methods: *We conducted a comprehensive narrative review of recent mechanistic advances, bioengineering innovations, and clinical trial data regarding stem cell–derived therapies for diabetes. Data sources included peer-reviewed publications, clinical trial registries, and landmark case studies reporting outcomes of pluripotent stem cell (PSC)-derived β-cell constructs, mesenchymal stem cells (MSCs), hematopoietic stem cells (HSCs), and engineered islet organoids.*

Results: *Preclinical studies have established robust protocols for differentiating PSCs into glucose-responsive β-cells and islet-like organoids, with engineered enhancements improving graft survival, vascularization, and metabolic resilience. Early-phase clinical trials demonstrate feasibility and efficacy. For example, autologous approaches achieve long-term insulin independence in a T2D patient using induced pluripotent stem cell–derived islets, whereas allogeneic constructs restored C-peptide production and eliminated severe hypoglycemia in T1D patients, with the majority achieving insulin independence. Gene-edited, hypoimmune islets in preclinical primates demonstrated long-term insulin independence without immunosuppression, highlighting the feasibility of off-the-shelf platforms. Further, engineered MSCs secreting GLP-1 and FGF21 improved glycemia and lipid metabolism in models, suggesting systemic cardiometabolic benefit beyond insulin replacement.*

Conclusions: *Stem cell–based therapies for diabetes have progressed from theoretical promise to early clinical reality. Evidence now supports durable β-cell function, improved glycemic control, and reduced insulin dependence in both T1D and T2D. Remaining challenges include ensuring long-term graft stability, vascularization, and immune protection, as well as establishing scalable, GMP-compliant manufacturing. Next-generation trials integrating immune-evasive engineering, vascularized scaffolds, and personalized autologous sources are poised to redefine diabetes care, shifting the paradigm from chronic management toward durable disease modification and potential cure.*

Keywords
Stem cell therapy, β-cell replacement, Islet organoids, Type 1 diabetes, Type 2 diabetes, Regenerative medicine.

Introduction
For the first time, regenerative therapies have demonstrated durable insulin independence in patients with type 1 (T1D) and type 2 diabetes(T2D), marking a translational inflection point. This review synthesizes the biological, engineering, and clinical advances driving this paradigm shift. Combined prevalence of T1D and T2D is projected to rise sharply (~46%) by 2050 [1]. Current standard-of-care therapies, including exogenous insulin and pharmacologic agents, are effective for glycemic control but fail to prevent long-term disease progression, reverse β-cell loss, or restore durable endogenous insulin production [2]. This therapeutic gap has accelerated interest in regenerative approaches. Among these, stem cell–based strategies represent the most advanced and clinically translatable interventions, offering the potential not only to improve glycemic regulation but also to achieve functional cure [3].

Clinical evidence supporting the paradigm shift beyond glycemic control to reversal of metabolic dysfunction is accumulating. Early-phase trials using mesenchymal stem cells (MSCs), induced pluripotent stem cells (iPSCs), and embryonic stem cell–derived β-cell therapeutic strategies have demonstrated safety, immunomodulatory effects, and preliminary efficacy in both T1D and T2D. Notably, ongoing trials such as VX-880 and VCTX211 are evaluating stem cell–derived islet replacements in patients with T1D, while recent case reports extend feasibility to T2D. Wu and colleagues [4] provided the first clinical demonstration of personalized endoderm stem cell–derived islet tissue restoring insulin production and enabling insulin independence in a T2D patient. These findings underscore the growing translational maturity of stem cell therapies, moving from theoretical promise to patient-level benefit.

At the mechanistic level, advances in β-cell biology are facilitating the refinement of therapeutic strategies. Pancreatic β-cells are central to glucose homeostasis. Approaches coupling nutrient sensing with insulin secretion through ATP-sensitive K^+ channel signaling and Ca^{2+}-mediated granule exocytosis have provided platforms for continued advancement [5]. New insights into β-cell adaptability have also reshaped clinical trial design. For example, Perez-Frances et al. demonstrated that β-cell–only grafts can achieve physiologically adaptive insulin secretion *in vivo,* even without α- or δ-cell input [6]. This simplifies differentiation protocols, reduces manufacturing complexity, and informs the selection of endpoints in clinical studies evaluating engineered β-cell constructs.

Parallel advances in bioengineering and genetic modification are expanding the scope of clinical applications. Strategies such as incorporating growth factors, metabolic modulators, and protective gene edits into stem cell–derived β-cells have improved graft survival and reduced glucotoxicity. In preclinical models, engineered MSCs expressing fibroblast growth factor 21 (FGF21) and glucagon-like peptide-1 (GLP-1) enhanced both glycemic control and lipid metabolism [2], suggesting that stem cell therapies may deliver systemic metabolic benefits beyond insulin replacement. Emerging organoid technologies (e.g., $Procr^+$ progenitor–derived islets, chemically induced pluripotent stem cells (CiPSCs), and endoderm stem cell–derived organoids) offer scalable, patient-specific, and physiologically robust constructs that can be translated into standardized manufacturing platforms suitable for clinical trial deployment.

Taken together, these developments define a translational inflection point. Stem cell–based interventions are no longer confined to theoretical or preclinical exploration but are actively entering clinical testing pipelines. The next generation of trials must therefore be designed not only to demonstrate safety and efficacy but also address durability, scalability, and cost-effectiveness. This requires harmonization of biological insights with trial design features encompassing vast constructs from patient selection, endpoints, immune modulation strategies, to long-term monitoring. The purpose of this review is to synthesize current mechanistic and engineering advances, align them with the state of clinical trial readiness, and outline the path toward scalable, safe, and durable stem cell–based therapies for diabetes.

β-Cell Biology and Functional Insulin Secretion
Pancreatic β-cells serve as the principal effectors of glucose homeostasis, orchestrating nutrient sensing—via mechanisms such as glucokinase-mediated ATP generation and Ca^{2+}-triggered exocytosis—and integrating paracrine and hormonal cues to precisely regulate insulin secretion [7]. Under physiological conditions, glucose uptake through GLUT2 transporters drives glycolytic flux and oxidative phosphorylation, raising the ATP/ADP ratio, closing ATP-sensitive potassium channels, and triggering voltage-gated calcium influx to promote insulin granule exocytosis [8]. Beyond glucose, β-cells integrate incretin, lipid, and neural signals to calibrate insulin output with systemic metabolic demand [9]. This multifactorial regulation provides a mechanistic framework for defining functional endpoints in clinical trials of stem cell–derived islets, where the capacity for

stimulus-responsive insulin secretion remains the gold standard for efficacy. Recent discoveries have refined our understanding of β-cell adaptability, with direct implications for graft design and trial strategies. Perez-Frances et al. demonstrated that pancreatic islets composed exclusively of β-cells preserved physiologically relevant glucose-regulated insulin secretion *in vivo* (i.e., biphasic release dynamics, mitochondrial activation, responsiveness to GLP-1 agonism) despite the complete absence of α-, δ-, and γ-cell–derived paracrine stimuli. These findings challenge entrenched assumptions regarding the necessity of intra-islet paracrine crosstalk, reinforcing the viability of streamlined differentiation strategies that emphasize β-cell purity for regenerative diabetes therapies. More recently, Jun et al. [10] demonstrated vascularized stem cell -islets will enable crosstalk between β cells and endothelial cells serving as an *in vitro* platform for disease modeling and therapeutic testing. Taken together, these studies suggest that β-cell–focused constructs can maintain functional efficacy while simplifying manufacturing requirements, an insight with significant implications for scalability, regulatory approval, and the clinical translation of stem cell–based diabetes interventions.

The translational implications of β-cell–focused and vascularized islet constructs are beginning to be realized in early clinical experience. Notably, Wu et al. [11] reported a first-in-human intervention using patient-specific, endoderm stem cell–derived islet tissue in an individual with type 2 diabetes, which restored endogenous insulin production and achieved sustained insulin independence. This landmark case demonstrates the feasibility of generating autologous, metabolically integrated islet-like grafts, bridging the gap between preclinical proof-of-concept and therapeutic application. From a clinical trial design perspective, such outcomes establish pragmatic benchmarks for efficacy endpoints (i.e., namely insulin independence, durable HbA1c reduction, C-peptide recovery) that can guide the evaluation of next-generation regenerative diabetes therapies. In parallel, bioengineering approaches are enhancing graft durability and systemic benefit. Lu et al. [12] demonstrated that incorporating growth factors, metabolic modulators, and gene edits into stem cell–derived β-cells improves glucose sensitivity and reduces susceptibility to glucotoxic stress. Complementary work by Xue et al showed that MSCs engineered to express fibroblast growth factor 21 (FGF21) and glucagon-like peptide-1 (GLP-1) improved glycemic control and lipid metabolism in preclinical models, broadening the therapeutic scope beyond insulin replacement. These findings underscore the possibility that next-generation β-cell constructs could address both glycemic dysregulation and cardiometabolic comorbidities, informing trial endpoints that extend beyond glucose control alone. As the integration of β-cell biology with stem cell engineering advances, the clinical trajectory is shifting from proof-of-concept safety studies to efficacy-driven trials designed to demonstrate durable glycemic control, metabolic benefit, and long-term graft survival. Collectively, these systems offer the potential not merely to replicate but to surpass native β-cell function, positioning engineered islets as a leading candidate for disease-modifying therapy in diabetes.

Stem Cell–Derived Islet Replacement Strategies

Building on this trajectory, stem cell–derived islet replacement strategies represent the most mature and scalable approach to restoring physiological insulin secretion. By generating functional β-cells or complete islet-like organoids from renewable pluripotent sources, these therapies aim to overcome the limitations of donor islets, broaden patient access, and establish a reproducible, regulated pathway for curative intervention in both T1D and T2D. Unlike cadaveric islet transplantation, which is constrained by donor scarcity and immune incompatibility, stem cell–based systems offer the potential for scalable manufacturing, reduced reliance on donor tissue, and the prospect of patient-specific autologous grafts [13,14]. These features are particularly critical as islet transplantation programs remain constrained by donor scarcity and logistical complexity, while regulatory agencies increasingly emphasize scalable, standardized cell manufacturing.

Against this backdrop, autologous bone marrow–derived therapies emerged as one of the earliest clinically tested regenerative strategies, offering a patient-specific source of progenitor cells with the potential to enhance β-cell regeneration and improve metabolic outcomes. Jawale et al. [15] demonstrated that infusion of autologous bone marrow mononuclear cells (BMMNCs) into multiple compartments (e.g., omental pouch, peritoneal cavity, intravenously) was safe and associated with durable improvements in glycemic control and β-cell function in patients with long-standing T1D. Cai et al. extended these findings in a randomized pilot trial by co-transplanting BMMNCs with umbilical cord–derived mesenchymal stem cells (MSCs) via the pancreatic artery, leading to enhanced endogenous C-peptide secretion, reduced HbA1c, and improved glucose metabolism compared with controls. In newly diagnosed T1D, Mesples et al. [16] reported that hepatic artery infusion of autologous BMMNCs reduced islet autoantibody titers and preserved C-peptide at 12 months, suggesting early immune modulation and β-cell preservation.

Building on these observations, combination approaches that integrate HSCs with MSCs are emerging as a promising avenue, with the potential to couple immunoregulatory effects with enhanced regenerative capacity. Thakkar et al. [17] demonstrated that co-infusion of autologous HSCs with adipose-derived insulin-secreting MSCs improved glycemic control and insulin dependence in patients with T1D, supporting the concept of multi-lineage synergy. While co-administration protocols remain underexplored, emerging data suggest that MSCs may enhance graft survival by exerting immunomodulatory and trophic effects, complementing the β-cell regenerative potential of HSCs.

Autologous hematopoietic stem cell transplantation (AHST) has been evaluated extensively in newly diagnosed T1D. Voltarelli et al. reported insulin independence in 14 of 15 patients after AHST, with follow-up extending up to 36 months. Subsequent trials confirmed improved C-peptide responses and reduced autoantibody titers [18], although conditioning-related toxicities remain a limiting factor [19,20]. Couri et al. [21] recently reinforced these findings, demonstrating that AHST can prolong

the honeymoon phase of T1D, reduce insulin requirements, and improve β-cell function. These data support AHST as a proof-of-concept for immune reset in T1D, while underscoring the need for safer conditioning regimens in next-generation trials. In parallel, standalone autologous MSC infusion has also shown encouraging early results. In a randomized controlled trial, Carlsson et al. [22] demonstrated that intravenous autologous MSC therapy in newly diagnosed T1D preserved or augmented C-peptide secretion at one year, contrasting with the progressive decline in untreated controls. Importantly, MSC therapy was associated with anti-inflammatory immune polarization, suggesting dual benefits in preserving β-cell mass and attenuating autoimmunity. Collectively, these findings demonstrate that stem cell–based strategies, spanning autologous BMMNCs, MSCs, HSCs, and engineered combinations, are clinically feasible and biologically active in T1D. Future trials will need to address durability, optimize delivery routes, and balance efficacy with safety, particularly in protocols requiring immune conditioning. These lessons are directly informing the design of next-generation stem cell–derived islet replacement therapies, which increasingly integrate insights from β-cell biology, bioengineering, and immunomodulation to advance toward durable, scalable cures.

Differentiation Pathways and Source Selection

Directed differentiation protocols have matured, moving beyond proof-of-principle toward reproducible, clinically relevant β-cell production. Early strategies that mimicked embryonic development through sequential induction of definitive endoderm, pancreatic progenitors, and endocrine precursors established the foundation for stem cell–based islet replacement [23]. More recent refinements have enhanced the fidelity and scalability of differentiation by optimizing growth factor timing, hypoxic conditioning, and three-dimensional (3D) culture platforms, producing β-cells with increasingly native-like insulin secretory profiles [24].

Current-generation protocols exploit a diverse array of sources, including pluripotent stem cells, adult progenitors, and transdifferentiated somatic cells. Precise modulation of Wnt, TGF-β, and Notch signaling has emerged as a cornerstone for achieving functional glucose responsiveness and minimizing off-target lineage specification [25]. These advances are not merely technical but have direct clinical relevance: consistency in β-cell differentiation underpins regulatory approval for investigational new drug (IND) applications and ensures that clinical trials evaluate reproducible, scalable products rather than bespoke laboratory constructs.

Clinical Translation Milestones

Landmark First-in-Human Case in Type 2 Diabetes. Wu et al. [11] conducted a first-in-human, investigator-initiated trial (ClinicalTrials.gov NCT05294822) utilizing autologous endoderm stem cell–derived islet tissue (E-islets) for a patient with long-standing T2D and impaired islet function. The patient's peripheral blood mononuclear cells were reprogrammed into human induced pluripotent stem cells (hiPSCs), differentiated into endoderm stem cells (EnSCs), and further matured into functional E-islets. Following percutaneous portal vein infusion, the patient transitioned from requiring exogenous insulin to insulin independence by week eleven. At 113 weeks post-transplant, HbA_1c declined from 6.6% to 4.6%, accompanied by a more than twofold increase in fasting C-peptide levels and markedly improved glycemic variability and Time-in-Tight-Range (>99%, up from 57%). This landmark case underscores key trial readiness accomplishments for proof-of-concept of functional cure in advanced T2D, demonstrated long-term safety and efficacy (116 weeks follow-up), and offers benchmark outcomes (insulin independence, glycemic control, endogenous insulin secretion) for future trial endpoints.

*VX-880 Phase 1/2 Open-Label Trial in T1D***.** The VX-880 Phase 1/2 open-label trial in adults with T1D assessed an allogeneic, fully differentiated, stem cell–derived islet therapy. In the initial cohort, all 12 participants achieved $HbA_1c < 7\%$ and Time-in-Range > 70%. Ten of 12 became insulin-independent, and the remainder showed a ~92% reduction in exogenous insulin use, severe hypoglycemia was eliminated, and safety outcomes were consistent with expected profiles of immunosuppression. These results marked a critical inflection point in which replicable outcomes across multiple subjects with robust efficacy regardless of disease chronicity was demonstrated. Further, the trial established multi-center expansion into Norway, Switzerland, and the Netherlands. The VX-880 program represents an allogeneic, fully differentiated stem cell–derived islet therapy delivered under systemic immunosuppression, with efficacy replicated across multiple clinical centers, underscoring its scalability and reproducibility. In contrast, the landmark report by Wu et al. demonstrated the feasibility of an autologous, patient-specific approach, in which iPSC-derived islets restored durable insulin independence in a single individual with T2D, with follow-up extending beyond two years. Together, these trials illustrate two divergent yet complementary translational strategies: one prioritizing scalability through off-the-shelf allogeneic platforms, and the other emphasizing personalization through autologous constructs that may mitigate immune rejection. The field will need to determine whether convergence of these paradigms, leveraging the reproducibility of allogeneic therapies with the immune advantages of autologous systems, can deliver curative outcomes at population scale.

CiPSC-Derived Islets: Personalized Autologous Option in T1D. A Phase 1 trial reported the first transplantation of chemically induced pluripotent stem cell (CiPSC)–derived islets into a T1D patient. At one-year follow-up, the 25-year-old woman achieved and maintained complete insulin independence, with sustained HbA_1c reductions and favorable safety outcomes. This approach offers a personalized autologous option, potentially reducing immunogenicity and the need for long-term immunosuppression.

Hypoimmune Engineered Islets in Nonhuman Primates. In a pivotal nonhuman primate model, hypoimmune engineered stem cell–derived islets were transplanted into a fully allogeneic, immunocompetent diabetic cynomolgus monkey. Remarkably, the animal became insulin-independent long term without

immunosuppression and showed normalized C-peptide and glucose levels with no adverse effects. This study demonstrates the feasibility of creating hypoimmune islets that can function in immunocompetent hosts, potentially eliminating the need for immunosuppressive therapies.

Integrating Advanced Delivery, Personalization, and Trial Design. While diabetes trials now increasingly blend cell- and drug-based modalities, advanced drug delivery systems (DDS), though not yet applied to islet therapy, offer a conceptual parallel: improved pharmacokinetics, targeted delivery, reduced off-target effects, and synergy with pharmacogenomics, biomarker guidance, and AI personalization. Contemporary designs have the potential to incorporate adaptive dosing, tailor immune conditioning regimens, use real-time biomarker-driven endpoints, and support scalable manufacturing strategies. As such, the field is transitioning from laboratory optimization to real-world application. As such, cell-based interventions are now positioned alongside pharmacologic and device-based therapies as legitimate candidates for disease-modifying treatment.

Islet Organoids and Biofabrication Approaches

Islet organoid technologies are expanding the therapeutic toolkit by generating multicellular constructs that more faithfully replicate the structural and functional complexity of native islets. Unlike β-cell–only grafts, these organoids integrate α- and δ-cells to restore paracrine cross-talk, thereby enhancing dynamic glucose regulation and resilience to metabolic stress [26,27]. Importantly, this level of multicellular fidelity may influence trial endpoints, where metrics such as glucagon counter-regulation and hypoglycemia avoidance become relevant alongside insulin secretion.

Biofabrication advances are accelerating the maturation of transplantable organoids. Microfluidic bioreactor platforms deliver continuous nutrient exchange and waste removal, promoting functional β-cell development and enabling standardized large-scale production [28]. Three-dimensional bioprinting allows precise spatial patterning of endocrine, endothelial, and stromal components, yielding vascularizable constructs designed for host integration after transplantation [29]. A persistent translational challenge remains the establishment of durable vascular networks. ECM-derived scaffolds incorporating laminin-511 and collagen IV have been shown to enhance angiogenesis, improve β-cell survival, and sustain in vivo insulin secretion [30]. Further innovations include incorporation of angiogenic growth factors, pre-vascularization strategies, and biomaterials that combine encapsulation with local immunomodulatory factor release to mitigate immune rejection [31,32]. Together, these approaches are converging on clinically viable platforms that could support long-lasting graft function without the morbidity of chronic systemic immunosuppression.

Allogeneic vs. Autologous Sources

Building on these innovations in angiogenesis, pre-vascularization, and biomaterial-mediated immunomodulation, the field is now evaluating the relative merits of allogeneic versus autologous cell sources for islet replacement. Autologous iPSC-derived islets offer unmatched immune compatibility but face prohibitive costs and long production timelines, whereas allogeneic cell banks enable scalable, off-the-shelf therapies but require immune modulation. This dichotomy reflects a tension between personalization and scalability that will shape the regulatory and commercial trajectory of stem cell therapies [33]. Allogeneic stem cell lines, particularly those engineered for "immune stealth" through CRISPR-mediated deletion of MHC class I/II genes, offer scalable, off-the-shelf alternatives with lower per-unit costs [34]. Complementary strategies, including overexpression of immune checkpoint ligands (PD-L1, HLA-G) or modulation of NK-cell signaling, aim to further extend graft survival [35,36]. Nonetheless, immune engineering alone does not resolve persistent challenges such as graft survival, vascular integration, functional stability, and large-scale reproducibility, issues compounded in autologous sources by donor variability, particularly in older or metabolically compromised patients [37].

Translational success requires overcoming barriers beyond immune compatibility. The key barrier is long-term graft survival without chronic immunosuppression, rapid vascularization, prevention of dedifferentiation, and GMP-compliant scalability [38]. Product safety and function remain heavily influenced by cell source. Autologous MSCs may be impaired by age-related decline, inflammation, or metabolic stress, while allogeneic MSCs benefit from standardized manufacturing and healthy donor sourcing but demand strategies to limit host immune responses [39]. Advances in reprogramming, gene editing, and preconditioning are improving both autologous and allogeneic platforms, enhancing engraftment, β-cell support, and immunomodulatory potency [40].

Engineering Enhanced Stem Cells for Metabolic Modulation

Beyond β-cell replacement, engineered stem cells can be designed to target systemic metabolic dysfunction in both T1D and T2D. MSCs engineered to co-express FGF21 and GLP-1 reduced hyperglycemia, improved insulin sensitivity, and corrected dyslipidemia in a T2D mouse model, highlighting the potential of combinatorial engineering to address both glycemic control and metabolic syndrome. Such combinatorial engineering highlights that stem cell therapies may evolve from β-cell replacement into systemic metabolic platforms, potentially competing with GLP-1RAs and dual agonists. In addition, synthetic gene circuits embedded in β-cells enable glucose-responsive, feedback-regulated insulin release, offering precision control to minimize hypoglycemia risk [41]. Further, MSCs inherently secrete pro-angiogenic and anti-inflammatory factors that protect β-cells and enhance engraftment; coupling these traits with targeted metabolic payloads could yield synergistic therapeutic profiles [42].

Translation Toward Combination Therapies

Emerging evidence suggests that stem cell–derived β-cell replacement will be most effective when deployed as part of multimodal therapeutic regimens. Lu et al. [43] highlight the potential of combination strategies where engineered islet

constructs are paired with pharmacologic agents or immune modulators to maximize graft survival and systemic metabolic benefit. Early clinical reports reinforce this paradigm: in the ViaCyte/CRISPR Therapeutics trial (NCT04786262), implantation of gene-edited allogeneic pancreatic progenitors was combined with systemic immunosuppression, yielding detectable C-peptide secretion and reduced exogenous insulin requirements in patients with long-standing type 1 diabetes. Ongoing second-generation trials are testing whether immune-evasive edits can obviate the need for chronic immunosuppression while sustaining metabolic efficacy. These studies frame engineered β-cells not merely as insulin-replacement devices but as dynamic metabolic platforms capable of delivering continuous disease-modifying signals.

Immunoprotection and Immune Evasion

Encapsulation technologies remain central to immunoprotection, with macro- and micro-encapsulation devices currently being evaluated in Phase I/II trials (e.g., PEC-Encap, NCT02239354; PEC-Direct, NCT03162926). While immune isolation has shown proof of concept, pericapsular fibrotic overgrowth and oxygen diffusion limits have restricted long-term efficacy [44,45]. Parallel strategies employing gene editing to generate "hypoimmunogenic" grafts are advancing rapidly, with preclinical demonstration of survival across MHC-mismatched recipients [46,47]. First-in-human trials of multiplexed immune-edited iPSC-derived islets are anticipated within the next two years, positioning universal donor platforms as scalable off-the-shelf solutions. Encapsulation strategies provide immediate immune isolation but are limited by pericapsular fibrosis and oxygen diffusion, whereas gene-edited hypoimmune islets bypass encapsulation by directly evading alloimmunity. These approaches represent contrasting philosophies: one emphasizing a device-mediated barrier, the other a cell-intrinsic solution. Future platforms may converge, combining encapsulation with immune engineering to maximize both graft survival and safety.

Vascularization and Engraftment

The success of stem cell–derived islet grafts hinges on rapid revascularization. Clinical transplantation studies consistently show that inadequate vascular integration predicts early graft attrition [48]. Current Phase I studies are incorporating co-delivery of endothelial progenitors or VEGF-releasing scaffolds to accelerate angiogenesis and improve oxygenation (NCT05210530). Advanced imaging modalities, such as intravital microscopy and PET tracers for perfusion, enabling direct correlation between neovascularization kinetics and metabolic outcomes [49].

Functional Stability and Avoidance of Dedifferentiation

Long-term data from allogeneic islet trials highlight that functional decline remains a barrier even in immunologically protected grafts [49]. Recent preclinical work has shown that modulation of transcriptional stabilizers (e.g., PDX1, MAFA) and metabolic conditioning prior to transplantation can mitigate β-cell dedifferentiation under chronic hyperglycemia [50]. Clinical strategies now integrate metabolic "priming" with adjunctive agents such as GLP-1 receptor agonists and SGLT2 inhibitors to optimize the recipient milieu prior to engraftment [51].

Manufacturing, Quality Control, and Regulatory/Ethical Considerations

Manufacturing remains a decisive bottleneck. GMP-compliant differentiation protocols are being refined for reproducibility, with fully automated closed-system bioreactors now supporting the production of billions of β-cells per batch [52] Regulatory guidance is evolving: in its 2024 statement, the EMA emphasized the necessity of multi-layered release testing, including genomic stability, off-target editing analysis, and functional glucose responsiveness, prior to trial approval [53] Ethical challenges persist regarding stem cell sourcing, equitable patient access, and pricing transparency, necessitating early engagement with patients and public stakeholders to build trust in first-in-class regenerative products.

Table 1: Summary of recent landmark studies with therapeutic relevance.

Study	Year	Model/System	Key Findings	Therapeutic Relevance
Pagliuca et al., *Cell* [58]	2014	hESC-derived β-like cells	Generated glucose-responsive, insulin-secreting cells in vitro	Provided first proof-of-principle for large-scale β-cell generation
Millman et al., *Nat Commun* [59]	2016	Stem cell-derived islets	Enhanced insulin secretion and functional maturation via modified differentiation protocols	Advanced functional capacity toward native human islets
Velazco-Cruz et al., *Cell Stem Cell*	2019	hPSC-derived islets	Improved maturation using extended culture and transplantation into mice	Demonstrated enhanced glucose-stimulated insulin secretion post-transplant
Nair et al., *Sci Transl Med* [60]	2019	Encapsulated hPSC-derived islets	Achieved long-term glycemic control in diabetic mice without immunosuppression	Validated encapsulation as viable immune-protective strategy
Hogrebe et al., *Nat Biotechnol* [61]	2020	hPSC differentiation	Modulated Wnt and TGF-β signaling to enhance β-cell lineage specification	Provided mechanistic insights for improving yield and purity of β-cells
Balboa et al., *Diabetologia* [62]	2021	Gene-edited SC-islets	Knockout of HLA class I to evade immune detection	Opened pathway for universal donor islet products
Yoshihara et al., *Cell Reports* [63]	2022	SC-islets + vascularization scaffold	Enhanced graft survival and function with pre-vascularized devices	Addressed revascularization bottleneck for transplanted islets

Future Directions in Stem Cell–Based Diabetes Therapy

The field is transitioning from first-in-human feasibility toward scalable clinical deployment. It is likely that the next decade will witness leveraging iPSC derivation, single-cell transcriptomics, and predictive modeling to generate patient-specific grafts tuned for autoimmunity risk and metabolic phenotype [54]. The integration of adjunctive biologics, i.e., engineered islets with immune tolerance induction (e.g., low-dose IL-2), metabolic regulators (FGF21 analogs), and anti-inflammatory biologics to extend graft survival and enhance systemic outcomes is also on the horizon [55]. Moreover, ECM-mimetic scaffolds, microfluidic vascularization, and bioprinting to generate islet organoids with native-like cytoarchitecture and on-demand production capacity continue to advance [56]. Great strides are also being made with digital integration such as incorporation of biosensors within encapsulation devices to enable real-time monitoring of graft function and immune activity, coupled with AI-driven feedback for adaptive therapeutic adjustments [57]. Scaling access will depend on international consortia to establish shared GMP facilities, harmonized regulatory pathways, and equitable cost frameworks to ensure availability beyond high-resource settings.

Conclusions

The next decade will determine whether stem cell–derived islets transition from experimental validation to mainstream therapy. Success hinges on scalable GMP manufacturing, immune-evasive editing, and long-term graft stability. If achieved, these innovations could position regenerative cell therapy as the first disease-modifying cure for diabetes Stem cell–derived therapies for diabetes have advanced from experimental models to early clinical validation, with multiple trials demonstrating engraftment, regulated insulin secretion, and measurable glycemic benefit in patients with long-standing disease. The emerging vision extends beyond β-cell replacement toward engineered, metabolically active constructs capable of modulating systemic physiology. Progress in immune-evasive editing, vascularized biofabrication, and clinical-grade manufacturing now sets the stage for transformative therapies.

Realizing this potential will require a coordinated, multidisciplinary effort spanning basic discovery, clinical trial infrastructure, long-term registries, and policy innovation. If aligned with principles of safety, accessibility, and global equity, stem cell–based interventions may shift diabetes care from lifelong management to durable, functional cure within the coming decade.

References

1. GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Lond Engl. 2023; 402: 203-234.
2. Xue B, Xiao X, Yu T, et al. Mesenchymal stem cells modified by FGF21 and GLP1 ameliorate lipid metabolism while reducing blood glucose in type 2 diabetic mice. Stem Cell Res Ther. 2021; 12: 133.
3. Yau AWN, Chia AYY. Advancements in diabetes research and stem cell therapy: a concise review. J Diabetes Metab Disord. 2025; 24: 130.
4. Ghoneim MA, Gabr MM, El-Halawani SM, et al. Current status of stem cell therapy for type 1 diabetes: a critique and a prospective consideration. Stem Cell Res Ther. 2024; 15: 23.
5. Ashcroft FM. ATP-sensitive potassium channelopathies: focus on insulin secretion. J Clin Invest. 2005; 115: 2047-2058.
6. Perez-Frances M, Bru-Tari E, Cohrs C, et al. Regulated and adaptive in vivo insulin secretion from islets only containing β-cells. Nat Metab. 2024; 6: 1791-1806.
7. Rutter GA, Gresch A, Delgadillo Silva L, et al. Exploring pancreatic beta-cell subgroups and their connectivity. Nat Metab. 2024; 6: 2039-2053.
8. Ashcroft FM, Rorsman P. Diabetes mellitus and the β cell: the last ten years. Cell. 2012; 148: 1160-1171.
9. Seedat F, Holden K, Davis S, et al. A new paradigm of islet adaptations in human pregnancy: insights from immunohistochemistry and proteomics. Nat Commun. 2025; 16: 6687.

Table 2: Stem Cell–Derived Islet Replacement Clinical Trials.

Trial/Product	Sponsor	Approach	Delivery Site/Device	Phase/Status	Key Outcomes
Zimislecel (VX-880)	Vertex	Stem cell–derived islets	Hepatic portal vein (infusion)	Phase 1/2, ongoing	Restored C-peptide; insulin independence in some participants
VX-264	Vertex	Same cells as VX-880 with device	Subcutaneous, channel-array encapsulation device	Phase 1/2, Part B dosing complete	Day-90 analyses complete; safety maintained
VC-02 / PEC-Direct	ViaCyte	PEC-01 pancreatic endoderm cells	Open device (vascularizing); requires immunosuppression	Phase 1/2	Insulin secretion observed with immunosuppression
VC-01 / PEC-Encap	ViaCyte	PEC-01 pancreatic endoderm cells	Encapsulation device (immunoisolating, subcutaneous)	Terminated/iterated	Limited function due to pericapsular fibrosis
VCTX210A	CRISPR Tx + ViaCyte	Gene-edited hypoimmunogenic pancreatic endoderm	Subcutaneous device (combination product)	Phase 1, ongoing	First-in-human dosing; safety being assessed

10. Jun Y, Nguyen-Ngoc KV, Sai S, et al. Engineered vasculature induces functional maturation of pluripotent stem cell-derived islet organoids. Dev Cell. 2025; 60: 2455-2469.
11. Wu J, Li T, Guo M, et al. Treating a type 2 diabetic patient with impaired pancreatic islet function by personalized endoderm stem cell-derived islet tissue. Cell Discov. 2024; 10: 45.
12. Ogieuhi IJ, Agbo CE, Ajekiigbe VO, et al. Stem cell-derived pancreatic beta cells: a step closer to functional diabetes treatment? BMC Endocr Disord. 2025; 25: 181.
13. Shapiro AMJ, Pokrywczynska M, Ricordi C, et al. Clinical pancreatic islet transplantation. Nat Rev Endocrinol. 2017; 13: 268-277.
14. Millman JR, Pagliuca FW. Autologous Pluripotent Stem Cell-Derived β-Like Cells for Diabetes Cellular Therapy. Diabetes. 2017; 66: 1111-1120.
15. Wu Z, Huang S, Li S, et al. Bone marrow mesenchymal stem cell and mononuclear cell combination therapy in patients with type 2 diabetes mellitus: a randomized controlled study with 8-year follow-up. Stem Cell Res Ther. 2024; 15: 339.
16. Mesples AD, Cox DCT, Lundy HD, et al. Monitoring of Autoantibodies Following Autologous Hematopoietic Stem Cell Transplantation in 6 Children with Recently Diagnosed Type 1 Diabetes Mellitus. Med Sci Monit. 2023; 29: e938979.
17. Thakkar UG, Vanikar AV, Trivedi HL, et al. Co-infusion of autologous adipose tissue derived insulin-secreting mesenchymal stem cells and bone marrow derived hematopoietic stem cells: viable therapy for type III.C. a diabetes mellitus. Biomed J. 2013; 36: 304-307.
18. Voltarelli JC, Couri CEB, Stracieri ABPL, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA. 2007; 297: 1568-1576.
19. Ye L, Li L, Wan B, et al. Immune response after autologous hematopoietic stem cell transplantation in type 1 diabetes mellitus. Stem Cell Res Ther. 2017; 8: 90.
20. Madani S, Amanzadi M, Aghayan HR, et al. Investigating the safety and efficacy of hematopoietic and mesenchymal stem cell transplantation for treatment of T1DM: a systematic review and meta-analysis. Syst Rev. 2022; 11: 82.
21. Couri CEB, Malmegrim KCR, Oliveira MC, et al. New Horizons in the Treatment of Type 1 Diabetes: More Intense Immunosuppression and Beta Cell Replacement. Front Immunol. 2018; 9: 1086.
22. Carlsson PO, Schwarcz E, Korsgren O, et al. Preserved β-cell function in type 1 diabetes by mesenchymal stromal cells. Diabetes. 2015; 64: 587-592.
23. Jin W, Jiang W. Stepwise differentiation of functional pancreatic β cells from human pluripotent stem cells. Cell Regen Lond Engl. 2022; 11: 24.
24. Mohandas S, Gayatri V, Kumaran K, et al. New Frontiers in Three-Dimensional Culture Platforms to Improve Diabetes Research. Pharmaceutics. 2023; 15: 725.
25. Alnasser SM, Alrobian AS, Alfayez MS, et al. Pharmacological modulation of stem cells signaling pathway for therapeutic applications. Stem Cell Res Ther. 2025; 16: 327.
26. Jiang L, Shen Y, Liu Y, et al. Making human pancreatic islet organoids: Progresses on the cell origins, biomaterials and three-dimensional technologies. Theranostics. 2022; 12: 1537-1556.
27. Velazco-Cruz L, Song J, Maxwell KG, et al. Acquisition of Dynamic Function in Human Stem Cell-Derived β Cells. Stem Cell Rep. 2019; 12: 351-365.
28. Pollock SD, Galicia-Silva IM, Liu M, et al. Scalable generation of 3D pancreatic islet organoids from human pluripotent stem cells in suspension bioreactors. STAR Protoc. 2023; 4: 102580.
29. Parvaneh S, Kemény L, Ghaffarinia A, et al. Three-dimensional bioprinting of functional β-islet-like constructs. Int J Bioprinting. 2023; 9: 665.
30. Hao D, Swindell HS, Ramasubramanian L, et al. Extracellular Matrix Mimicking Nanofibrous Scaffolds Modified with Mesenchymal Stem Cell-Derived Extracellular Vesicles for Improved Vascularization. Front Bioeng Biotechnol. 2020; 8: 633.
31. Xiong Y, Berggren PO. Vascularizing stem cell-derived islets: A blueprint for functional maturation. Dev Cell. 2025; 60: 2385-2387.
32. Foster GA, García AJ. Bio-synthetic materials for immunomodulation of islet transplants. Adv Drug Deliv Rev. 2017; 114: 266-271.
33. Marei HE. Stem cell therapy: a revolutionary cure or a pandora's box. Stem Cell Res Ther. 2025; 16: 255.
34. Floy ME, Shabnam F, Simmons AD, et al. Advances in Manufacturing Cardiomyocytes from Human Pluripotent Stem Cells. Annu Rev Chem Biomol Eng. 2022; 13: 255-278.
35. Tavakoli S, Samareh-Salavati M, Rahnama MA, et al. Natural killer cell therapy in hepatocellular carcinoma: a comprehensive review. Discov Oncol. 2025; 16: 1348.
36. Kim H. Overcoming Immune Barriers in Allogeneic CAR-NK Therapy: From Multiplex Gene Editing to AI-Driven Precision Design. Biomolecules. 2025; 15: 935.
37. Manjili MH. Redefining the Immunobiology of Organ Transplantation for New Clinical Horizons. Scand J Immunol. 2025; 102: e70045.
38. Yado S, Luboshits G, Hazan O, et al. Long-term survival without graft-versus-host-disease following infusion of allogeneic myeloma-specific Vβ T cell families. J Immunother Cancer. 2019; 7: 301.
39. Ahmed OTF, Ahmed ZT, Dairi AW, et al. The inconclusive superiority debate of allogeneic versus autologous MSCs in treating patients with HFrEF: a systematic review and meta-analysis of RCTs. Stem Cell Res Ther. 2025; 16: 175.
40. Raigani M, Eftekhari Z, Adeli A, et al. Advancing gene editing therapeutics: Clinical trials and innovative delivery systems

across diverse diseases. Mol Ther Nucleic Acids. 2025; 36: 102666.

41. Kerper N, Ashe S, Hebrok M, et al. Pancreatic β-Cell Development and Regeneration. Cold Spring Harb Perspect Biol. 2022; 14: a040741.
42. García-Guerrero CA, Fuentes P, Araya MJ, et al. How to enhance MSCs therapeutic properties? An insight on potentiation methods. Stem Cell Res Ther. 2024; 15: 331.
43. Lu K, Brauns T, Sluder AE, et al. Combinatorial islet protective therapeutic approaches in β-cell transplantation: Rationally designed solutions using a target product profile. FASEB BioAdvances. 2023; 5: 287-304.
44. Hu S, de Vos P. Polymeric Approaches to Reduce Tissue Responses Against Devices Applied for Islet-Cell Encapsulation. Front Bioeng Biotechnol. 2019; 7: 134.
45. Coron AE, Kjesbu JS, Kjærnsmo F, et al. Pericapsular fibrotic overgrowth mitigated in immunocompetent mice through microbead formulations based on sulfated or intermediate G alginates. Acta Biomater. 2022; 137: 172-185.
46. Kadyk LC, Okamura RM, Talib S, et al. Enabling allogeneic therapies: CIRM-funded strategies for immune tolerance and immune evasion. Stem Cells Transl Med. 2020; 9: 959-964.
47. Karpov DS, Sosnovtseva AO, Pylina SV, et al. Challenges of CRISPR/Cas-Based Cell Therapy for Type 1 Diabetes: How Not to Engineer a "Trojan Horse." Int J Mol Sci. 2023; 24: 17320.
48. Thorngren J, Brboric A, Vasylovska S, et al. Efficient Vascular and Neural Engraftment of Stem Cell-Derived Islets. Diabetes. 2024; 73: 1127-1139.
49. Maddahi J, Packard RRS. Cardiac PET perfusion tracers: current status and future directions. Semin Nucl Med. 2014; 44: 333-343.
50. Al Madhoun A, Bahman F, Ahmad R, et al. β-cell dedifferentiation in type 2 diabetes: Interplay of metabolic stress, endoplasmic reticulum dysfunction, and forkhead box protein O1 inhibition. World J Diabetes. 2025; 16: 109274.
51. So WY, Liao Y, Liu WN, et al. Paired box 6 gene delivery preserves beta cells and improves islet transplantation efficacy. EMBO Mol Med. 2023; 15: e17928.
52. Dadheech N, Bermúdez de León M, Czarnecka Z, et al. Scale up manufacturing approach for production of human induced pluripotent stem cell-derived islets using Vertical Wheel® bioreactors. NPJ Regen Med. 2025; 10: 24.
53. Cetin B, Erendor F, Eksi YE, et al. Advancing CRISPR genome editing into gene therapy clinical trials: progress and future prospects. Expert Rev Mol Med. 2025; 27: e16.
54. Paik DT, Chandy M, Wu JC, et al. Patient and Disease-Specific Induced Pluripotent Stem Cells for Discovery of Personalized Cardiovascular Drugs and Therapeutics. Pharmacol Rev. 2020; 72: 320-342.
55. Ma J, Li M, Yang L, et al. Pancreatic Islet Cell Hormones: Secretion, Function, and Diabetes Therapy. MedComm. 2025; 6: e70359.
56. Zhang S, Wan Z, Kamm RD, et al. Vascularized organoids on a chip: strategies for engineering organoids with functional vasculature. Lab Chip. 2021; 21: 473-488.
57. Farasati Far B, Safaei M, Nahavandi R, et al. Hydrogel Encapsulation Techniques and Its Clinical Applications in Drug Delivery and Regenerative Medicine: A Systematic Review. ACS Omega. 2024; 9: 29139-29158.
58. Pagliuca FW, Millman JR, Gürtler M, et al. Generation of functional human pancreatic β cells in vitro. Cell. 2014; 159: 428-439.
59. Millman JR, Xie C, Van Dervort A, et al. Generation of stem cell-derived β-cells from patients with type 1 diabetes. Nat Commun. 2016; 7: 11463.
60. Migliorini A, Nostro MC, Sneddon JB, et al. Human pluripotent stem cell-derived insulin-producing cells: A regenerative medicine perspective. Cell Metab. 2021; 33: 721-731.
61. Hogrebe NJ, Augsornworawat P, Maxwell KG, et al. Targeting the cytoskeleton to direct pancreatic differentiation of human pluripotent stem cells. Nat Biotechnol. 2020; 38: 460-470.
62. Balboa D, Barsby T, Lithovius V, et al. Functional, metabolic and transcriptional maturation of human pancreatic islets derived from stem cells. Nat Biotechnol. 2022; 40: 1042-1055.
63. Emoto N, Anazawa T, Yamane K, et al. A novel subcutaneous islet transplantation method using a bioabsorbable medical device to facilitate the creation of a highly vascularized transplantation site. Cell Transplant. 2025; 34: 9636897251342986.